Detalles de la búsqueda
1.
Quantitative high-throughput cell-based assays for inhibitors of ROCK kinases.
Methods Enzymol
; 439: 491-500, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18374184
2.
OSI-930: a novel selective inhibitor of Kit and kinase insert domain receptor tyrosine kinases with antitumor activity in mouse xenograft models.
Cancer Res
; 66(2): 1015-24, 2006 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-16424037
3.
KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells.
Clin Cancer Res
; 23(10): 2565-2574, 2017 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27815356
4.
Anti-KIT Monoclonal Antibody Treatment Enhances the Antitumor Activity of Immune Checkpoint Inhibitors by Reversing Tumor-Induced Immunosuppression.
Mol Cancer Ther
; 16(4): 671-680, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28138031
5.
Emerging Receptor Tyrosine Kinase Drug Targets: Implications for Antibody-Based Therapies for Oncology and Immunologic Disorders.
Crit Rev Oncog
; 20(5-6): 485-508, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-27279243
6.
ROCK1 and ROCK2 are required for non-small cell lung cancer anchorage-independent growth and invasion.
Cancer Res
; 72(20): 5338-47, 2012 Oct 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-22942252
7.
Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib.
Cancer Res
; 66(16): 8163-71, 2006 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-16912195
Resultados
1 -
7
de 7
1
Próxima >
>>